Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Spyre Therapeutics, Inc. Common Stock

SYRE

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Last trade $93.58
Day change -$5.795 (-5.83%)
Day range $85.71 – $100.97
Volume 680,981
Market cap $9.44B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$9.44B
Price / earnings
—
Price / book
8.97×
Price / sales
—
EV / sales
—
EV / EBITDA
-29.22×

Profitability

Earnings per share
-$2.36
Return on assets
-20.38%
Return on equity
-21.31%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
27.4×
Quick ratio
27.4×
Cash ratio
2.06×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$249.32M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SYRE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$16.55M$16.14M$15.23M$12.53M$11.64M$11.79M$11.94M$10.77M
Research and development$89.17M$65.5M$60.41M$44.64M$45.25M$40.15M$41.62M$50.48M
Total operating expenses$105.72M$81.64M$75.64M$57.17M$56.89M$51.94M$53.57M$61.25M
Operating income-$105.72M-$81.64M-$75.64M-$57.17M-$56.89M-$51.94M-$53.57M-$61.25M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$96.12M-$36.2M-$69.01M-$62.53M-$11.18M-$36.72M-$44.79M-$56.3M
Income taxes$0$0$0$0$0$0-$15K$1K
Net income-$96.12M-$36.2M-$69.01M-$62.53M-$11.18M-$36.72M-$44.77M-$56.3M
Net income attributable to common shareholders-$83.11M-$30.92M-$58.25M-$51.83M-$9.02M-$29.6M-$36.09M-$43.67M
EBITDA-$105.72M-$81.64M-$75.64M-$57.17M-$56.89M-$51.94M-$53.57M-$61.25M
Basic earnings per share-$0.94-$0.36-$0.74-$0.69-$0.15-$0.49-$0.60-$0.79
Diluted earnings per share-$0.94-$0.36-$0.74-$0.69-$0.15-$0.49-$0.60-$0.79

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

Spyre Therapeutics announced presentations of clinical and preclinical data for its three IBD antibodies (SPY001, SPY002, and SPY003) at UEGW 2026 in Barcelona. The company presented efficacy and safety data for these half-life extended antibodies in moderately to severely active ulcerative colitis, along with preclinical evidence showing additive efficacy of combination approaches. The SKYLINE study is testing these candidates as monotherapies and pairwise combinations, with combination results expected in 2027.

GlobeNewswire Inc.

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

Spyre Therapeutics priced its underwritten public offering at $85 per share, raising approximately $350 million in gross proceeds. The company plans to use the funds to advance its immunology programs in gastroenterology, rheumatology, and dermatology, including Phase 3 readiness and development of SPY072 for hidradenitis suppurativa. The offering is expected to close on October 7, 2026.

Zacks Investment Research

Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?

Spyre Therapeutics shares have declined 16.6% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a narrower-than-expected loss of 36 cents per share and benefited from a $40 million gain on asset sales, though R&D expenses surged 63.2% year-over-year. With $1.15 billion in cash expected to fund operations into late 2029, analyst estimates have shifted downward by 10.44%, and the stock holds a Zacks Rank #3 (Hold) rating.

GlobeNewswire Inc.

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, generating approximately $403 million in gross proceeds. The offering is expected to close on April 16, 2026. Joint book-running managers include Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC.

Benzinga

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

Spyre Therapeutics, a clinical-stage biotechnology company focused on inflammatory bowel disease treatments, announced a proposed underwritten public offering of $300 million in common stock, with an additional $45 million option for underwriters. The offering is subject to market conditions and regulatory approval, with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities serving as joint book-running managers.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 8, 20231-for-25reverse split